Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating Lymphocyte) Products

CAMBRIDGE, MA, USA I May 16, 2019 I Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced a research collaboration with Iovance Biotherapeutics, Inc. to assess the potential of applying Genocea’s neoantigen identification platform, ATLAS™, to next-generation TIL (tumor-infiltrating lymphocyte) product development.

“We are pleased to collaborate with Iovance, as they are recognized leaders in TIL therapies,” said Chip Clark, Genocea President & CEO, “and are excited to explore the utility of ATLAS, with its ability to identify and characterize neoantigens, in developing neoantigen-targeted TIL therapies, which would naturally complement our ongoing personalized cancer vaccine and cell therapy programs.”

Financial and other terms were not disclosed.

About Genocea Biosciences, Inc.
Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Our unique ATLAS technology platform allows us to identify immunotherapy targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude so-called “inhibitory” antigens that appear to exert an immunosuppressive effect on the patient. We are advancing complementary programs built from ATLAS insights:  GEN-009, our neoantigen vaccine candidate for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020. To learn more, please visit

SOURCE: Genocea Biosciences

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up